Wegovy
Wegovy is the higher-dose semaglutide formulation FDA-approved specifically for chronic weight management — same molecule as Ozempic, branded for the obesity market. Novo Nordisk added oral Wegovy (the pill version) in 2025, and the OASIS-4 trial supports a future sleep apnea indication. Our Wegovy coverage tracks real cash pricing, the oral vs injection tradeoffs, and dosing escalation.